About: An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
Creator	Hayashi, Yoshio Manickam, Manoj Pillaiyar, Thanigaimalai Jung, Sang-Hun Namasivayam, Vigneshwaran
Source	Medline; PMC
abstract	[Image: see text] Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10–15%) fatalities in 2003. The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CL(pro), has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection. Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications). This perspective focuses on the status of various efficacious anti-SARS-CoV 3CL(pro) chemotherapies discovered during the last 12 years (2003–2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening. We describe here mainly peptidomimetic and small molecule inhibitors of SARS-CoV 3CL(pro). Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.
has issue date	2016-02-15(xsd:dateTime)
bibo:doi	10.1021/acs.jmedchem.5b01461
bibo:pmid	26878082
has license	bronze-oa
sha1sum (hex)	a15589c1fa21d728e9bc7dddca37daeaaa4f2080
schema:url	https://doi.org/10.1021/acs.jmedchem.5b01461
resource representing a document's title	An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
has PubMed Central identifier	PMC7075650
has PubMed identifier	26878082
schema:publication	Journal of Medicinal Chemistry
resource representing a document's body	covid:a15589c1fa21d728e9bc7dddca37daeaaa4f2080#body_text
is schema:about of	named entity 'CHEMOTHERAPY' named entity 'OVERVIEW' named entity 'PROTEASE INHIBITORS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'CONDITIONS' named entity 'COMPLETE' named entity 'RESEARCH' named entity 'SMALL MOLECULE' named entity 'SMALL MOLECULE' named entity 'FATALITIES' named entity 'DESCRIPTION' named entity 'BINDING' named entity 'INFECTED' named entity 'HUMAN CORONAVIRUS' named entity 'VIRAL' named entity 'TREATMENT' named entity 'NOVEL' named entity 'MORE THAN' named entity 'SARS' named entity 'NATURAL PRODUCTS' named entity 'METHODS' named entity 'CAUSED BY' named entity 'EPIDEMIC' named entity '800' named entity 'INHIBITORS' named entity 'PERSPECTIVE' named entity 'CAUSATIVE AGENT' named entity 'PEPTIDOMIMETICS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'EFFECTIVE' named entity 'CURRENTLY' named entity 'SYNTHETIC' named entity 'SOURCES' named entity 'CHEMOTHERAPIES' named entity 'ESSENTIAL' named entity 'FEATURES' named entity 'TO PROVIDE' named entity 'VARIOUS' named entity 'INFECTION' named entity 'PROTEASE' named entity 'PRO' named entity 'DESCRIBE' named entity 'HERE' named entity 'REPLICATION' named entity 'STATUS' named entity 'YEARS' named entity '3500' named entity 'INCLUDING' named entity 'DRUG TARGET' named entity 'THESE' named entity 'SARS-COV' named entity 'IDENTIFIED' named entity 'LABORATORY' named entity '8000' named entity 'HAVE' named entity 'PEPTIDOMIMETIC' named entity 'NEWLY' named entity 'CORONAVIRUS' named entity 'INDIVIDUALS' named entity 'ITS' named entity 'STRUCTURAL' named entity 'PUBLICATIONS' named entity 'VIRTUAL SCREENING' named entity 'small molecule inhibitors' named entity 'causative agent' named entity 'SARS-CoV' named entity 'peptidomimetic' named entity 'human coronavirus' named entity 'SARS' named entity 'SARS-CoV' named entity 'Protease Inhibitors' named entity 'Cys' named entity 'SARS' named entity 'peptides' named entity 'coronaviruses' named entity 'CoV' named entity '2.6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software